ShockWave Medical, Inc. SWAV

Full chart Compare
Set alert

Price alert · SWAV

All alert types
334.75 0.00 (+0.00%)

At closeMay 30, 2024, 4:00 PM EDT

334.75 Day range 334.90

52-week range unavailable

Market cap
12.57B
Revenue (ttm)
787.97M
Profit margin
20.75%
Shares out
37.54M
Forward P/E
55.70
Volume
3.95M
Open
334.85
Previous close
334.75
Day's range
334.75 – 334.90
Beta
0.88
Analysts
Hold
Price target
324.27 (-3.1%)
Earnings date
May 6, 2024

2Y +170.54 (+103.85%)

200300Aug 22Jan 23May 23Oct 23Mar 24334.75

Key statistics

Enterprise value
12.32B
PEG ratio
2.63
Price / sales
15.95
Price / book
16.70
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
35.80%
Free cash flow
118.03M
Total cash
1.03B
Total debt
776.80M
Return on equity
24.73%
Short % of float
5.50%
50-day average
326.86
200-day average
241.38

Financials — quick view

All financials
SWAV Revenue — quarterly 218.81M
2020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 2024
SWAV Net income — quarterly 55.35M
2020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 2024
SWAV EPS — quarterly 1.48
2020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 2024

Earnings

SWAV recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
May 6, 2024Mar 1, 20241.04———
Feb 15, 2024Dec 1, 20230.92———
Nov 6, 2023Sep 1, 20230.81———
Aug 7, 2023Jun 1, 20230.87———
May 8, 2023Mar 1, 20230.81———
Feb 16, 2023Dec 1, 20220.99———

Upgrades / downgrades

SWAV analyst upgrades and downgrades
DateFirmActionFromTo
Oct 15, 2023Leerink Partnersinit—Outperform
Sep 28, 2023UBSinit—Neutral
Aug 9, 2023Morgan StanleymainOverweightOverweight
Aug 7, 2023Wells FargomainEqual-WeightEqual-Weight
Aug 7, 2023NeedhammainBuyBuy
Jul 9, 2023Morgan StanleyupEqual-WeightOverweight

About ShockWave Medical, Inc.

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California. As of May 31, 2024, Shockwave Medical, Inc. operates as a subsidiary of Johnson & Johnson.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on SWAV — it syncs with the Stock Master app.

Insider holders

SWAV insider holders
InsiderRelationLatest transactionDateShares held
FRANCIS LAURA A.DirectorStock GiftMar 25, 20244,784
GAETA RENEEChief Financial OfficerStock Award(Grant)Feb 4, 202419,890
GODSHALL DOUGLAS EVANChief Executive OfficerSaleFeb 14, 2024162,762
MOLL FREDERIC HDirectorSaleFeb 20, 2024287,521
PAPIERNIK ANTOINEDirectorConversion of Exercise of derivative securityJul 4, 202334,913
PHUNG TRINH TUOfficerStock GiftMay 21, 202450,387

Institution ownership

SWAV institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.89%3,636,4441.04BJun 29, 2023
Vanguard Group Inc9.80%3,603,0141.03BJun 29, 2023
FMR, LLC6.63%2,434,974694.97MJun 29, 2023
Wellington Management Group, LLP3.68%1,352,723386.08MJun 29, 2023
Artisan Partners Limited Partnership3.12%1,147,784327.59MJun 29, 2023
Price (T.Rowe) Associates Inc2.97%1,091,050311.40MJun 29, 2023

Fund ownership

SWAV fund ownership
Holder% heldSharesValueReported
iShares Core S&P Midcap ETF3.13%1,149,365228.84MSep 29, 2023
Vanguard Total Stock Market Index Fund3.12%1,145,905327.05MJun 29, 2023
Vanguard Small-Cap Index Fund2.57%945,622269.89MJun 29, 2023
Smallcap World Fund1.59%585,000166.96MJun 29, 2023
Vanguard Small-Cap Growth Index Fund1.47%540,949154.39MJun 29, 2023
Price (T.Rowe) Health Sciences Fund1.42%520,729148.62MJun 29, 2023